Eijkman's Merah Putih Vaccine Approaching Preclinical Testing

The development of the Merah Putih Vaccine studied by the Eijkman Molecular Biology Research Center (PRBM) has entered the downstream stage at PT Bio Farma and is getting closer to the preclinical and clinical process.

PRBM researcher Eijkman of the National Research and Innovation Agency (BRIN) Tedjo Sasmono in a written statement received in Jakarta, Tuesday, said that currently the development of the Merah Putih Vaccine being researched by their team is in the downstream stage at an industrial partner, namely PT Bio Farma. He hopes that in the near future, preclinical and clinical trials will be carried out. "Hopefully the COVID-19 vaccine by the nation's children can contribute to the prevention of the pandemic and become a vehicle for the nation's independence in vaccine research," he said. Acting Head of PRBM Eijman Wien Kusharyoto said research on the COVID-19 vaccine with a recombinant protein sub-unit platform was still in the process of being developed. "The production is also in accordance with the level indicated by the industry, in this case PT Bio Farma," he said.

|•SOURCE•| Articles : | Image :Klikdokter |

READ MORE

|• NATIONAL •|Communal Immunity Path
|• INTERNATIONAL •|Behind License Revocation
|• RELIGION •|Happiness the ultimate goal life
|• TIPS AND WISDOM •|Work provides creative
|• SCIENCE •|IKN Moves to East Kalimantan